gender/age Refraction Visual acuity CCT um VF PD 2005 VF PD 2012 IOP Therapy
RE LE RE LE RE LE RE LE RE LE RE LE
F/62 -2 -2 1 1 556 542 2.06 1.64 2.06 2.05 12 12 timolol
F/64 1 1 1 1 558 560 2.15 2.63 3.53 3.00 16 16 carteolol
F/70 1 2 1 1 580 580 1.65 1.35 1.88 1.37 17 17 timolol
F/61 0 0 1 1 540 544 5.88 3.02 5.90 3.05 13 16 betaxolol
F/63 -2.25 0 1 1 570 565 1.64 1.42 2.49 2.19 20 20 carteolol
F/63 0 0 1 1 540 546 2.80 2.47 2.08 1.62 13 13 carteolol
F/63 2 2 1 1 534 540 2.19 2.00 1.59 2.00 15 15 timolol
F/69 1 1 1 1 545 533 1.98 3.25 2.03 2.85 14 14 timolol
F/67 0 0 1 1 567 572 2.09 2.49 1.78 2.71 14 14 betaxolol
F/70 0 0 1 1 543 557 2.82 2.35 2.35 2.63 10 10 timolol
F/53 0 0 1 1 565 564 1.79 2.02 1.58 1.18 16 18 betaxolol
F/54 2 2 1 1 570 564 1.82 1.67 1.67 1.71 18 16 betaxolol
F/68 0 0 1 1 570 570 1.75 2.14 1.30 1.07 11 11 timolol
F/70 1.5 1.5 1 1 561 550 1.36 2.31 0.93 1.02 17 17 carteolol
F/59 -2 -3 1 1 559 560 1.65 1.62 2.28 2.31 13 14 betaxolol
F/57 1 1 1 1 535 534 2.24 2.62 2.63 2.42 16 17 betaxolol
F/65 -5 -5 1 1 562 567 1.74 4.63 1.57 1.75 15 15 vistagan
F/64 2 2 1 1 544 544 2.76 1.85 1.55 1.34 16 17 timolol
M/60 0 0 1 1 567 581 20.00 22.95 21.00 22.14 12 12 timolol
M/53 0 0 1 1 550 550 1.01 1.44 1.57 1.46 14 14 carteolol
M/56 1 1 1 1 578 570 1.65 1.99 1.75 1.99 15 16 carteolol
M/66 0 0 1 1 540 540 2.51 1.75 3.11 1.59 10 13 timolol
M/50 -3.5 -3.5 1 1 542 543 18.32 4.97 18.27 4.70 15 15 timolol
M/52 0 0 1 1 539 538 1.71 1.54 1.98 1.76 15 15 betaxolol
M/69 0 0 1 1 539 548 2.62 1.66 2.65 1.70 15 12 timolol
M/60 1 1 1 1 570 565 1.21 1.69 1.33 1.48 18 17 carteolol
M/70 1 1 1 1 560 570 2.03 3.08 1.74 1.83 10 11 carteolol
M/69 0 0 1 1 550 550 2.41 1.72 1.60 1.71 14 14 timolol
M/69 0 0 1 1 551 552 1.98 2.60 0.87 1.92 19 19 betaxolol
M/62 2 2 1 1 580 580 2.38 3.28 3.18 3.41 14 13 betaxolol
Table 1: SC values in the control group.